Prostate Cancer - Results from #2160

The association between beta-blockers use and prostate cancer mortality: A mini systematic review and meta-analysis. September 18, 2023

A Machine Learning Framework Reduces the Manual Workload for Systematic Reviews of the Diagnostic Performance of Prostate Magnetic Resonance Imaging. September 15, 2023

Systemic therapy escalation after stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer. September 15, 2023

Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience. September 15, 2023

Recurrent Gleason Score 6 Prostate Cancer After Radiotherapy or Ablation: Should We Observe Them All? Results from a Large Multicenter Salvage Radical Prostatectomy Consortium. September 15, 2023

Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U. September 15, 2023

Prostate Biopsy in the Case of PIRADS 5-Is Systematic Biopsy Mandatory? September 14, 2023

Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer. September 14, 2023

Lesion Dosimetry for [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer. September 14, 2023

Prognostic significance of serum testosterone level in patients with castration-resistant prostate cancer treated with cabazitaxel. September 14, 2023

Selecting the optimal radiation modality in prostate cancer. September 14, 2023

Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer. September 14, 2023

Perspectives on prostate cancer: advances and pending challenges for a multidisciplinary oncological approach in South America. September 14, 2023

The androgen receptor does not directly regulate the transcription of DNA damage response genes. September 14, 2023

Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers. September 14, 2023

Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer. September 14, 2023

Racial differences in serum chemokines in prostate cancer patients. September 14, 2023

Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression. September 14, 2023

Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance. September 14, 2023

Prostate Cancer Reshapes the Secreted and Extracellular Vesicle Urinary Proteomes. September 14, 2023

Page 109 of 1439